NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

This trial tests whether an experimental drug called ONS-5010 (a form of bevacizumab) works as well as an approved drug, Lucentis, for treating wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the eye. Abo…

This early-phase study tested a new drug called ASKG712 in 56 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The drug is injected into the eye and works by blocking two proteins that fuel abnormal blood vessel growth. The main goals were t…

This study tested whether a pre-filled syringe of the medicine SB11 (a biosimilar to ranibizumab) is easy for eye doctors to use. Thirty adults with wet age-related macular degeneration, macular edema from retinal vein occlusion, or myopic choroidal neovascularization received on…

This study tested three different doses of SYL1801 eye drops in 99 people with wet age-related macular degeneration (AMD). The goal was to see if the drops are safe and can improve or maintain vision. Participants used the drops for a set period, and their vision was measured aft…

This study tested a new medication, LUBT010, against the standard drug Lucentis for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. Six hundred participants received monthly injections into the eye for one year. The goal was to see if LUBT0…

This early-stage trial tested a new drug called PMC-403 in 17 people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The drug is injected directly into the eye. The main goal was to check safety and find the best dose for future studies. The tria…

This early-stage study tested a new drug called OLX10212 in 21 people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal was to see if the eye injections are safe and tolerable. Researchers also looked for early signs that the drug migh…

This study tested whether adding a light-based treatment (photodynamic therapy) to the standard drug ranibizumab could reduce the number of eye injections needed for wet macular degeneration. Sixty adults over age 50 with the condition took part. The goal was to see if the combin…

This study tested a new drug called FYB203, which is a biosimilar (a close copy) of the existing medication Eylea, for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The trial involved 434 participants and compared how well FYB203 worked v…

This completed Phase 4 study tested how much of the drug aflibercept gets into the bloodstream when a high dose (8 mg) is injected into both eyes of adults with diabetic macular edema or wet age-related macular degeneration. Fifty-one participants received the injections and had …

This study looked at the long-term safety of faricimab, a drug injected into the eye, for people with wet age-related macular degeneration (AMD). Over 1,000 participants who had completed earlier studies received faricimab at personalized intervals. The main goal was to track sid…

This phase 2 trial tested carbidopa-levodopa (Sinemet), a drug usually used for Parkinson's disease, in 20 people with wet age-related macular degeneration (AMD). The goal was to see if the drug is safe and can improve vision or reduce retinal swelling. Participants took the pill…

This phase 2 trial tested carbidopa-levodopa, a drug used for Parkinson's disease, in 35 people with wet age-related macular degeneration (AMD). The goal was to see if the drug could improve vision and reduce the need for standard anti-VEGF eye injections. Participants took the o…

This study tests a drug called carbidopa-levodopa (Sinemet), typically used for Parkinson's disease, in people with wet age-related macular degeneration (AMD). It is a 9-month extension for 35 participants who completed an earlier study. The goal is to see if the drug can help ma…

This study measured the thickness of the conjunctiva and Tenon's capsule (outer eye layers) in 736 people with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME), and in healthy volunteers of similar age. Researchers used a special eye scanner (SD…

This study looked at over 550,000 people who received Eylea® injections for eye conditions to find out how often retinal vasculitis (a rare eye inflammation) occurs. Researchers used a large US registry and medical records to confirm cases. The goal was to better understand the s…